physiciansweekly.com
Disturbed Brain-Gut Interactions May Fuel Fatigue in Remitted Crohn's Disease
Fatigue is a common, often persistent symptom in Crohn’s disease even during remission. This study suggests brain structure differences may be linked to fatigue when inflammation is low, pointing to potential noninflammatory causes and future treatment targets.
Adults with Crohn’s disease, clinicians treating IBD-related fatigue, and researchers studying brain–gut interactions or fatigue mechanisms.
What To Know
What to know This article reports on a prospective observational study linking brain structure and fatigue in people with Crohn’s disease (CD). The researchers compared healthy controls, patients with active CD, and patients in remission and measured fatigue (WEIMuS), anxiety/depression (HADS), fecal calprotectin, and cranial MRI gray matter volume (GMV).
They found correlations between higher fatigue scores and lower GMV in specific brain regions (left precentral gyrus, right fusiform gyrus, right lingual gyrus), with some relationships stronger in remitted CD.
The authors note that impaired brain–gut interactions may play a role in persistent fatigue when inflammation is absent, and they suggest future studies to explore noninvasive brain stimulation (for example, transcranial magnetic stimulation) as a potential therapeutic approach if structural brain changes are confirmed.
What this does and does not show The study identifies associations between fatigue and regional GMV but does not establish causation or show that altering brain structure will improve fatigue. The sample sizes were modest (23 remitted CD, 30 active CD, 37 controls), and findings need replication.
Clinical care for CD should not be changed based on this single observational study. Practical takeaway Researchers and clinicians interested in fatigue in IBD may consider brain–gut mechanisms and imaging biomarkers in future studies.
Patients experiencing persistent fatigue may find it helpful to discuss symptom management with their care team, but this article does not provide treatment recommendations.
This is an observational imaging study with modest group sizes and cannot prove cause and effect. Fecal calprotectin and MRI were used as objective measures; results require replication and clinical trials before changing care. The original Journal of Crohn’s and Colitis paper is the primary source for full methods and data.
